Loading...
Loading...
Browse all stories on DeepNewz
VisitFederal Judge Dismisses WCAS from FTC Antitrust Lawsuit Against USAP
May 14, 2024, 06:00 PM
A federal judge in Texas, Judge Hoyt, has dismissed private equity firm Welsh Carson Anderson & Stowe (WCAS) from a major antitrust lawsuit brought by the Federal Trade Commission (FTC). The lawsuit accused WCAS and its portfolio company, U.S. Anesthesia Partners (USAP), of suppressing competition and driving up prices for anesthesiology services in Texas through serial acquisitions of practices. While the judge allowed the case to proceed against USAP, WCAS was dismissed as a defendant. This ruling represents a significant setback for the Biden administration's efforts to regulate private equity firms more strictly.
View original story
No significant change • 33%
Decrease in stock prices • 33%
Increase in stock prices • 33%
Significant negative impact • 33%
Minor negative impact • 33%
No significant impact • 34%
Significant financial loss • 33%
No significant financial impact • 33%
Financial gain (increased publicity) • 34%
Significant negative impact • 25%
No significant impact • 25%
Significant positive impact • 25%
Moderate impact • 25%
Significant negative impact • 33%
Minor negative impact • 33%
No impact • 34%
Increase in U.S. operations • 25%
No change in U.S. operations • 25%
Decrease in U.S. operations • 25%
Cease U.S. operations • 25%
Significantly positive impact • 25%
Moderately positive impact • 25%
Neutral impact • 25%
Negative impact • 25%
Increase in market share • 33%
No change • 33%
Decrease in market share • 34%
Significant negative impact • 25%
Minor negative impact • 25%
No impact • 25%
Positive impact • 25%
Significant financial loss • 33%
Minor financial impact • 33%
No financial impact • 34%
Positive impact on DeFi market • 33%
Negative impact on DeFi market • 33%
No significant change • 34%
Significant negative impact • 25%
Minor negative impact • 25%
No significant impact • 25%
Positive impact • 25%
Decrease in WCAS related stocks • 34%
Increase in WCAS related stocks • 33%
No significant change in WCAS related stocks • 33%